| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/30/2004 | EP1433783A2 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 06/30/2004 | EP1433780A1 19-nor-vitamin D3 compounds with calcemic activity |
| 06/30/2004 | EP1433484A1 Use of interleukin-18 for treating skin disorders associated with UV radiation |
| 06/30/2004 | EP1433483A1 Reovirus for the treatment of neoplasia wherein double stranded RNA-activated protein kinase (PKR) is inactivated or deleted |
| 06/30/2004 | EP1433479A1 Appetite-stimulating agents and remedies for anorexia |
| 06/30/2004 | EP1432821A2 A method for the early detection of cancer |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432799A2 Silencing of gene expression by sirna |
| 06/30/2004 | EP1432792A2 Histone deacetylase 9 |
| 06/30/2004 | EP1432791A1 Alphavirus replicon vector systems |
| 06/30/2004 | EP1432788A2 Live attenuated salmonella strains for producing vaccines |
| 06/30/2004 | EP1432737A2 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor |
| 06/30/2004 | EP1432736A2 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) |
| 06/30/2004 | EP1432735A2 Antagonistic anti-htnfsf13b human antibodies |
| 06/30/2004 | EP1432734A1 Cytokine receptor |
| 06/30/2004 | EP1432732A2 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432721A1 Process for the preparation of rebeccamycin and analogs thereof |
| 06/30/2004 | EP1432715A2 Pyrimidine derivatives |
| 06/30/2004 | EP1432714A2 Chemical compounds |
| 06/30/2004 | EP1432711A1 1,6-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432710A1 1, 8-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432709A1 1-glyoxlylamide indolizines for treating cancer |
| 06/30/2004 | EP1432708A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
| 06/30/2004 | EP1432706A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
| 06/30/2004 | EP1432703A1 Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| 06/30/2004 | EP1432702A1 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |
| 06/30/2004 | EP1432699A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432698A2 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| 06/30/2004 | EP1432697A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432691A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
| 06/30/2004 | EP1432689A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders |
| 06/30/2004 | EP1432687A2 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 06/30/2004 | EP1432679A1 Preparation and use of pyrrole derivatives for treating obesity |
| 06/30/2004 | EP1432677A1 Novel urea oligomers, the preparation method thereof and pharmaceutical compositions containing same |
| 06/30/2004 | EP1432669A1 4-(c2-6 alkoxy)-substituted chalcones as therapeutic agents |
| 06/30/2004 | EP1432527A2 Biological control of nanoparticles |
| 06/30/2004 | EP1432454A2 Methods for sterilizing preparations containing albumin |
| 06/30/2004 | EP1432448A2 Novel molecules of the hkid-1-related protein family and uses thereof |
| 06/30/2004 | EP1432447A2 Combined compositions and methods for tumor vasculature coagulation and treatment |
| 06/30/2004 | EP1432446A2 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
| 06/30/2004 | EP1432441A2 Use of hmgb1 for the activation of dendritic cells |
| 06/30/2004 | EP1432438A2 Use of rank antagonists to treat cancer |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432422A2 Use of c-kit inhibitors for the treatment of myeloma |
| 06/30/2004 | EP1432417A2 Substituted benzimidazole compounds and their use for the treatment of cancer |
| 06/30/2004 | EP1432416A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/30/2004 | EP1432413A2 3,4-methylenedioxy-substituted chalcones as therapeutic agents |
| 06/30/2004 | EP1432408A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 06/30/2004 | EP1432403A2 Liposome loading with metal ions |
| 06/30/2004 | EP1432402A2 Compositions for delivery of drug combinations |
| 06/30/2004 | EP1315730B1 1-(alkyl), 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo(1,2-a)pyrimidin-5(1h)-one derivatives |
| 06/30/2004 | EP1173413B1 Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |
| 06/30/2004 | EP1149072B1 Sulfonamide hydroxamates |
| 06/30/2004 | EP1054688B1 Method for selecting tumours expressing hla-g, sensitive to anticancer treatment and uses |
| 06/30/2004 | EP1009743B1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation |
| 06/30/2004 | EP1000053B1 Macrocyclic lactones, compositions, and methods of use |
| 06/30/2004 | EP0975640B1 Vinca alkaloid antimitotic halogenated derivatives |
| 06/30/2004 | EP0945436B1 Cytotrienins, process for preparing the same, and antitumor agent |
| 06/30/2004 | EP0690722B1 Composition and method for reducing toxicity of biologically-active factors |
| 06/30/2004 | CN1509337A New polynucleotides and polypeptides of IFN alpha-17 gene |
| 06/30/2004 | CN1509335A Topoisomerase I selective cytotoxic sugar derivatives of indolopyrrolocarbazoles |
| 06/30/2004 | CN1509292A Combination apparoach to treatment of cancer using C-MYC antisense oligomer |
| 06/30/2004 | CN1509291A Oxazolo-and-furopyrimidines and their use in medicaments against tumors |
| 06/30/2004 | CN1509286A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509283A Novel pyridyl cyanoguandine compounds |
| 06/30/2004 | CN1509278A N-phenyl-arylsulfonamide compound, drug comprising the compound as active ingredient, intermediate for the compound |
| 06/30/2004 | CN1509277A Process for preparing paclitaxel |
| 06/30/2004 | CN1509276A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509275A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509274A Metallo proteinase inhibitors |
| 06/30/2004 | CN1509273A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509272A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509271A 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for treatment of pain anxiety or gastrointestinal disorders |
| 06/30/2004 | CN1509270A Indolinons, substituted in position 6, and their preparation and use as kinase inhibitors |
| 06/30/2004 | CN1509188A Immunoconjugates made of egg-yolk antibiodies (IGY), production and use thereof in diagnoses and therapy |
| 06/30/2004 | CN1509187A Cytotoxic CD44 antibody immunoconjugates |
| 06/30/2004 | CN1509186A Composition containing epigallocatechin gallate |
| 06/30/2004 | CN1509182A Use of extracts and preparations from iris plants and tectorigenin as organ selective medicament for treating urethra disease |
| 06/30/2004 | CN1509174A Tartrate salt of 5,8,14-triazatetracyclo [10,3,1,02,11.04,9]-hexzdeca-2(11),3,5,7,9-pentaene |
| 06/30/2004 | CN1509171A Use of pyrazoline derivatives in preparation of medicament for prevention and/or treatment of proliferative cell diseases |
| 06/30/2004 | CN1508248A Tumour related gene and use thereof |
| 06/30/2004 | CN1508145A Anti-tumour ginseng saponin aglycone derivatives |
| 06/30/2004 | CN1508134A Anti-cance active substance of cyathocline purpurea and separating and purifying method thereof |
| 06/30/2004 | CN1507905A Chinese medicine composition for treating tumour |
| 06/30/2004 | CN1507884A Chinese medicine powder and decoction composition for treating cancers |
| 06/30/2004 | CN1507882A Medicine for treating lung cancer and preparing method thereof |
| 06/30/2004 | CN1507875A 肿瘤基因开关药物 Tumor gene switch drugs |
| 06/30/2004 | CN1507874A Tumour gene switch medicine |
| 06/30/2004 | CN1507873A 肿瘤基因开关药物 Tumor gene switch drugs |
| 06/30/2004 | CN1507869A Combined preparation containing morpholine anthracyclines and anticancer agent |
| 06/30/2004 | CN1507857A Elemene fatty emulsion injection and preparing method thereof |
| 06/30/2004 | CN1155620C Thioether conjugates |
| 06/30/2004 | CN1155615C Human protein with cancer cell growth suppressing function and its coding sequence |
| 06/30/2004 | CN1155614C Human protein with cancer cell growth suppressing function and its coding sequence |
| 06/30/2004 | CN1155610C Pristimerin series derivative possessing antioxidation and antitumour activity and its synthesis method |
| 06/30/2004 | CN1155601C Dioxacyclopentedien-6-(5aH)-one compound, its preparation process and medicinal composition |
| 06/30/2004 | CN1155600C 2,3-diaryl-pyrazolo[1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2(cox-2) inhibitors |
| 06/30/2004 | CN1155595C Substituted pyrroles as antiproliferative agents for treatment of cancer |
| 06/30/2004 | CN1155589C Compounds and methods for modulation of estroglen receptors |